**Name of journal: World Journal of Gastroenterology**

**ESPS Manuscript NO: 15587**

**Columns: ORIGINAL ARTICLE**

***Retrospective Cohort Study***

**Low RASSF6 expression in pancreatic ductal adenocarcinoma is associated with poor survival**

Ye HL *et al.* RASSF6 in pancreatic cancer

Hui-Lin Ye, Dou-Dou Li, Qing Lin, Yu Zhou, Quan-Bo Zhou, Bing Zeng, Zhi-Qiang Fu, Wen-Chao Gao, Yi-Min Liu, Rui-Wan Chen, Zhi-Hua Li, Ru-Fu Chen

**Hui-Lin Ye, Qing Lin, Yu Zhou, Quan-Bo Zhou, Bing Zeng, Zhi-Qiang Fu, Wen-Chao Gao, Ru-Fu Chen,** Department of Hepatobiliary Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, Guangdong Province, China

**Dou-Dou Li, Yi-Min Liu,** Department of Radiotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, Guangdong Province, China

**Rui-Wan Chen,** Department of Radiotherapy, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510120, Guangdong Province, China

**Zhi-Hua Li,** Department of Medical Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, Guangdong Province, China

**Author contributions:** Ye HLand Li DD contributed equally to this study; Ye HL and Lin Q performed the majority of experiments; Li DD conducted part of the experiment, and contributed to revise this paper; Li ZH and Chen RF conceived the experiments, analyzed and interpreted data and wrote the manuscript; Zhou Y, Zhou QB, Zeng B, Fu ZQ, Gao WC, Liu YM and Chen RW participated in the experiment and helped analyzed data; all authors read and approved the final manuscript.

**Ethics approval:** The study was reviewed and approved by the Institutional Review Board of Sun Yat-sen Memorial hospital and the Ethics Committee of Sun Yat-sen Memorial Hospital.

**Informed consent:** All study participants provided informed written consent prior to study enrollment.

**Conflict-of-interest:** The authors disclose no conflicts.

**Data sharing:** The technical appendix, statistical code, and dataset are available from the corresponding author at chenrf\_sysu@163.com. Consent was not obtained but the presented data are anonymized and the risk of identification is low.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Correspondence to: Dr. Ru-Fu Chen,** Department of Hepatobiliary Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, 107 Yan-Jiang Xi Road, Guangzhou 510120, Guangdong Province, China. chenrf\_sysu@163.com

**Telephone**: +86-21-81332020

**Fax**: +86-21-81332020

**Received:** November 29, 2014

**Peer-review started:** November 29, 2014

**First decision:** December 26, 2014

**Revised:** January 24, 2015

**Accepted:** February 12, 2015

**Article in press:**

**Published online:**

**Abstract**

**AIM**: To analyze RASSF6 expression in pancreatic ductal adenocarcinoma (PDAC) and to determine whether RASSF6 has an independent prognostic value in PDAC.

**METHODS**: We studied RASSF6 expression in 96 histologically confirmed PDAC samples and 20 chronic pancreatitis specimens using immunohistochemistry and real-time quantitative reverse transcription-PCR. PDAC issues were then classified as RASSF6 strongly positive, weakly positive or negative. RASSF6 mRNA and protein expression in PDAC samples with strong positive staining were further evaluated using real-time PCR and western blot analysis. Lastly, correlations between RASSF6 staining and patients’ clinicopathological variables and outcomes were assessed.

**RESULTS**: RASSF6 was negatively expressed in 51 (53.1%) PDAC samples, weakly positively expressed in 29 (30.2%) samples and strongly positively expressed in 16 (16.7%) specimens, while its expression was much higher in para-tumor tissues and chronic pancreatitis tissues. Positive relationships between RASSF6 expression and T-stage (*P* = 0.047) and perineural invasion (*P* = 0.026) were observed. The median survival time of strong and weak positive and negative RASSF6 staining groups was 33 mo, 15 mo and 11 mo, respectively. Cox multivariate analysis indicated that RASSF6 was an independent prognostic indicator of overall survival in patients with PDAC. A survival curve revealed that increased RASSF6 expression was correlated with better overall survival (*P* = 0.009).

**CONCLUSION:** RASSF6 expression is an independent biomarker of an unfavorable prognosis in patients with PDAC.

**Key words****:** Pancreatic cancer; Pancreatic ductal adenocarcinoma; Prognostic marker; RASSF6; K-*ras*; Immunohistochemistry; Survival analysis

**© The Author(s) 2015.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** This is the first study that provides evidence for the prognostic value and potential tumor suppressor activity of RASSF6 in pancreatic ductal adenocarcinoma. The prominent findings in this study are that RASSF6 is an independent prognostic marker for predicting the survival of pancreatic ductal adenocarcinoma patients after curative operations and that the expression of RASSF6 might decrease with the development of cancer.

Ye HY, Li DD, Lin Q, Zhou Y, Zhou QB, Zeng B, Fu ZQ, Gao WC, Liu YM, Chen RW, Li ZH, Chen RF. Low RASSF6 expression in pancreatic ductal adenocarcinoma is associated with poor survival. *World J Gastroenterol* 2015; In press

**INTRODUCETION**

Pancreatic cancer is a highly malignant neoplasm and the fourth-leading cause of cancer death. Pancreatic ductal adenocarcinoma (PDAC) accounts for the majority (> 90%) of pancreatic malignancies[[1](#_ENREF_1)]. The 5-year survival of PDAC is only approximately 5%, and this figure has remained nearly unchanged over the past two decades, but the incidence of PDAC has been rising worldwide[[2](#_ENREF_2),[3](#_ENREF_3)]. Unlike in breast and other carcinomas, no molecular markers have been established to date for estimating prognosis or providing information for treatment decision-making in patients with PDAC. The identification of biomarkers that accurately predict disease recurrence or response to chemotherapy would be of substantial aid in individual risk assessment and treatment selection and may even lead to novel therapies by becoming targets for molecular intervention in specific subsets of patients.

Common genetic changes have been validated in PDAC pathogenesis in several whole-genome sequencing studies. The genetic landscape of the PDAC genome is notable for 4 frequently mutated genes, including KRAS, CDKN2A/p16, TP53, and SMAD4/DPC4[[4](#_ENREF_4),[5](#_ENREF_5)]. Among all of the mutated genes, KRAS is among the earliest and most pervasive alteration in pancreatic carcinogenesis, and the KRAS gene is mutated in virtually all PDAC patients[[6-8](#_ENREF_6)]. In addition, a number of genetic studies have shown that such activating K-*ras* gene mutations are necessary for the onset of pancreatic cancer[[9](#_ENREF_9)]. An inducible pancreas-specific expression system was recently used to show that K-RASG12D expression is also required for tumor maintenance[[10](#_ENREF_10)]. These findings indicate the importance of K-*ras* gene in PDAC. However, K-*ras* gene showed low prognostic and predictive value because this gene was mutated in almost all of the PDAC patients.

The inappropriate activation of Ras proteins promotes a variety of malignant phenotypes, including enhanced growth, loss of contact inhibition, a reduced requirement for growth factors, enhanced motility and invasion and resistance to apoptosis[[11](#_ENREF_11)]. Interestingly, activated Ras can also induce various aspects of growth inhibition and death[[12-14](#_ENREF_12)]. RASSF family proteins have now been identified as potential mediators of some of the growth inhibitory effects of Ras, and RASSF family proteins are often down-regulated during tumorigenesis[[15](#_ENREF_15)]. RASSF6 was identified as a new negative effector of the RAS protein, which demonstrates a tumor suppressor function, including the inhibition of growth, promotion of cell cycle arrest, and induction of apoptosis[[16](#_ENREF_16)]. In 239-T cells, a dramatic synergistic activation of cell death was observed when the cells were transfected with activated K-RAS and RASSF6 together, and siRNA knockdown of RASSF6 expression in human lung tumor cells increases tumorigenicity[[15](#_ENREF_15)]. In addition, studies showed that the inactivation of RASSF6 is also an extremely frequent event in the pathogenesis of childhood leukemia[[17](#_ENREF_17)].

Collectively, these findings above indicate that RASSF6 might play an important role in regulating PDAC progression. However, to our knowledge, no data concerning the role of RASSF6 in PDAC is available. The objective of the current study was therefore to clarify the clinical implications of the status of RASSF6 in PDAC. We investigated the status of RASSF6 expression in pancreatitis tissues, PDAC primary lesions, and lymph node metastases, and evaluated the impact of RASSF6 expression on outcomes in patients undergoing resection for PDAC.

**MATERIAL AND METHODS**

***Patients and tissue specimens***

This study involved patients with PDAC undergoing radical operations in a retrospective study cohort between Jan 2000 and Jun 2012 at Sun Yat-sen Memorial Hospital of Sun Yat-sen University and a prospective cohort from Jun. 2012 to May 2013 (registration number: ChiCTR-TRC-12002548). The study was approved by the ethics committee of Sun Yat-sen Memorial Hospital, and all study participants provided informed written consent prior to study enrollment. Data were collected on age, sex, histological and pathological findings, lymph node metastasis, metastases, tumor grading disease stage (UICC 6th edition), and clinical follow-up. Patients who died of postoperative complications and patients lost during follow-up were excluded. Overall survival (OS) were calculated from the date of operation to the date of death or last follow-up. Through searching the electronic medical record system including the clinical and pathological records of inpatients, 96 surgical treated patients diagnosed with stage I, or II histologically confirmed PDAC were included.

***Immunohistochemical analysis***

Paraffin-embedded samples of the primary carcinomas from 96 patients were stained for RASSF6. The pathological sections were deparaffinized in xylene and rehydrated in a graded ethanol series followed by heat-induced epitope retrieval in citrate buffer (pH 6.0). Antigen retrieval was carried out in 10 mmol/L citrate buffer (pH 6.0) in a microwave oven for 15 min. The activity of endogenous peroxidase was exhausted with 3% hydrogen peroxide for 10 min at room temperature. A rabbit RASSF6 polyclonal antibody (Proteintech Group, Chicago, IL) was applied overnight at 4 ℃ at an optimal working concentration of 1:200. After sufficient phosphate buffered saline rinses, the sections were immunostained with goat anti-rabbit polymers. The staining was scored by two independent investigators, without knowledge of the patient outcomes, clinical features or pathological characteristics, according to the staining intensity and extent as described previously[[18](#_ENREF_18)]. The sum of staining intensity and extent was designated as follows: 0–2, negative expression; 3–4, weak expression; and 5–6, strong expression. If a disagreement occurred, the slides were re-examined to obtain a final consensus.

***RNA extraction, reverse transcription, and real-time RT-PCR***

The total RNA of 96 frozen primary pancreatic cancer tissues was prepared with Trizol (TRIzol, Invitrogen, United States) according to the manufacturer’s instructions and reverse transcribed into cDNA. The mRNA levels of RASSF6 and GAPDH were analyzed using the SYBR Green Realtime PCR Master Mix with gene-specific primers on the ABI 7500 Fast Real-Time PCR System, according to the manufacturer’s instructions. The primers for qRT-PCR were: RASSF6, sense 5’-AGCTGCCAGTTCTTGGAATG-3’ and antisense 5’-AGGCCAGACAGCTCTGATGT-3’; GAPDH, sense 5’-GTCCACCACCCTGTTGCTGTA-3’ and antisense 5’-CTTCAACAGCGACACCCACTC-3’. The cycle number at which the reaction crossed an arbitrarily placed threshold (Ct) was determined for each gene. The RASSF6 mRNA level for each tumor was calculated using the △Ct method: △Ct = CtRASSF6 - CtGAPDH.

***Western blot analysis***

The total protein content was extracted from frozen PDAC and para-tumor tissues stored in liquid nitrogen using a Whole Cell Extraction Kit (Pierce, Rockford, IL). For equal protein loading, a bicinchoninic acid protein assay kit (Pierce) was used to calculate the protein concentration in each sample. Equivalent amounts of proteins were separated by SDS-PAGE and transferred to polyvinylidene fluoride (PVDF) membranes for immunoblotting. The membranes were blocked in 5% fat-free milk for 2 h at room temperature and washed 3 times, and then the membranes were incubated with the following primary antibodies: a rabbit anti-human RASSF6 polyclonal antibody (1:1000, Proteintech Group, Chicago, IL) and a polyclonal rabbit anti-human β-actin polyclonal antibody (1:1000, Abcam, Cambridge, MA). β-Actin was used as a loading control. Horseradish peroxidase-conjugated secondary antibodies (Cell Signaling Technology) and an ECL chemiluminescence kit (Pierce) were used to detect the bound antibodies.

***Statistical analysis***

All of the statistical analyses were performed with the SPSS 16.0 statistical software package (SPSS Inc., Chicago, IL). Frequency distributions were compared by *χ*2 test. Continuous variables were compared using the Student t-test. The principal outcome measure was the length of survival as measured from the time of the original surgery. The patients alive at the time of the follow-up point were censored. The last follow-up period for patients still alive was May 2013. A Kaplan- Meier survival analysis was used to assess the significance of RASSF6 protein alone or together with other clinical factors. The significant differences between the survival curves were determined using the log-rank test. The 1-, 3- and 5-year survival rates were estimated using life tables. Variables that were significant after univariate analysis at *P* < 0.1 were included in multivariate analysis. Cox proportional hazards models were generated for multivariate analysis. A *P* value < 0.05 was considered to be statistically significant in a two-tailed test. The statistical methods of this study were reviewed by Professor Jing Gu from the School of Public Health of Sun Yat-sen University.

**RESULTS**

***Patient characteristics***

Demographic data and tumor characteristics are summarized in Table 1. The cohort of 96 patients consisted of 45 women and 51 men. The mean age at operation was 60.7 years, with a median age of 61 years and a range of 31–77. At the time of the last clinical follow-up (May 2013), 23 (24.0%) patients were alive. None of the patients died during the perioperative period because of post-operative complications. The median overall survival was 15.5 months, with 1-, 3-, and 5-year survival rates of 57.5%, 23.0%, and 14.0%, respectively, in all 96 patients. The majority of tumors were moderately differentiated (38.5%), followed by well differentiated (36.5%), and 25.0% of tumors were poorly differentiated. Most of the tumors (*n* = 81) were located in the head of the pancreas (84.4%), and 80 (83.3%) were more than 2.0 cm in maximal diameter. Eighty-one (84.4%) patients had T3 tumors. Lymph node metastases were present in 61 (63.5%) patients, and portal vein invasion was present in 12 (12.5%) of the 96 patients. All of the patients presented with the Union for International Cancer Control (UICC) stage I and II disease, and none of the patients presented with UICC stage III or IV disease. All of the patients had undergone primary curative resection, and 17 (17.7%) patients had a positive surgical margin. If indicated, patients received either gemcitabine-based or 5-FU-based chemotherapy as first-line chemotherapy according to their clinical disease stage and performance status.

***Immunohistochemical analysis***

The immunohistochemical analysis of RASSF6 was performed on the 96 primary lesions of pancreatic ductal adenocarcinoma and 20 resected lesions of chronic pancreatitis. Figure 1 represents the immunohistochemical results of RASSF6 expression in patients with pancreatic ductal adenocarcinoma and chronic pancreatitis. RASSF6 was detected in carcinoma cells in the tumor tissues and was localized predominantly in the cytoplasm, without nuclear staining. In addition, islet cells showed an extremely strong staining of RASSF6 expression. Tumor cytoplasmic expression of RASSF6 was classified as negative (Figure 1A), strongly positive (Figure 1B) and weakly positive (Figure 1C). Of the 96 patients with pancreatic cancer, 51 (53.1%) showed negative RASSF6 expression, 29 (30.2%) specimens had weak RASSF6 staining, and 16 (16.7%) specimens displayed strongly positive staining. Among the 20 patients with chronic pancreatitis, strong RASSF6 expression and weak RASSF6 expression was observed in 80% (16/20) and 20% (4/20) of cases, respectively.

***RASSF6 expression is down-regulated in primary PDAC tissues compared with adjacent normal tissues or chronic pancreatitis tissues***

Immunohistochemical analysis demonstrated a significantly higher proportion of positive RASSF6 staining in chronic pancreatitis compared with pancreatic cancer (Figure 1) (*P* = 0.015, Fisher’s exact test). In addition, qRT-PCR results revealed that the mRNA levels of RASSF6 were also down-regulated in PDAC compared with chronic pancreatitis (Figure 2A, *P* < 0.001). The relationshi*p* between the immunohistochemical stage of RASSF6 and its mRNA level was further evaluated (Figure 2B), and we found a clear difference in measured mRNA levels between negative, weak and strong RASSF6 staining groups. This finding indicates that the immunohistochemical scores are consistent with qRT-PCR results. Subsequently, RASSF6 mRNA expression and protein expression in 16 cases of PDAC samples with strong positive RASSF6 staining were evaluated using real-time PCR and western blot analysis. The results confirmed that RASSF6 protein and mRNA levels were significantly down-regulated in cancer tissues (Figure 2C and D).

***Expression of RASSF6 in tumor cells and correlation with clinicopathological parameters***

Tumors with perineural invasion demonstrated RASSF6 expression less frequency, and a significant association between RASSF6 expression level and the presence of perineural invasion was observed (*P* = 0.026; Table 1). In addition, RASSF6 expression seemed to be associated with the UICC T stage. We found that higher-stage tumors demonstrated RASSF6 expression less frequently with a significant difference at the boundary (Table 1). No significant association was observed between age, sex, location of tumor, differentiation, lymph node status, portal vein invasion, or surgical margins.

***Prognostic Impact of RASSF6 Expression***

Based on the immunohistochemical staining of RASSF6, 96 patients were then stratified into 3 groups (strong positive *vs* weak *vs* negative). Kaplan–Meier curves were constructed to determine whether RASSF6 expression was correlated with survival in these groups. The median survival time of the strongly positive group, weak group and negative group was 33 mo, 15 mo and 11 mo, respectively. In this cohort, there was a significant correlation between RASSF6 expression levels and overall survival (*P* = 0.009; Figure 3A). Compared with patients with negative RASSF6A expression, patients with both strong positive RASSF6 staining and weak RASSF6 staining showed improved overall survival time (strong positive vs. negative, *P* = 0.006; Figure 3B; weak *vs* negative, *P* = 0.047; Figure 3C). Furthermore, positive (weak and strong) RASSF6 expression was also strongly associated with an increased overall survival time compared with negative RASSF6 expression (*P* = 0.004) (Figure 3D).

The variables most likely to impact survival by univariate analysis (*P* ≤ 0.1) were entered into the multivariate analysis model (Table 2). Cox regression analysis demonstrated that negative RASSF6 expression remained an independent prognostic factor of poor prognosis (OR = 2.355, 95%CI: 1.413-4.300, *P* = 0.001).

**DISCUSSION**

For the first time, we examined the mRNA and protein expression of RASSF6 in PDAC and evaluated its prognostic value. We confirmed that both the protein and mRNA expression levels of RASSF6 were down-regulated in PDAC. In addition, down-regulation of RASSF6 is a predictor of poor survival outcome. Our findings suggested that RASSF6 was a valuable prognostic indicator of PDAC patients undergoing radical operations, and a decrease in RASSF6 expression might be associated with the progression of PDAC.

The Ras proteins perform their diverse functions by interacting with RASS effectors, which have conserved Ras interacting domains. The R A-domain, a type of Ras interacting domain, is a main characteristic of the Ras-association domain family (RASSF) proteins[[19](#_ENREF_19)]. RASSF family proteins have now been identified as potential mediators of some of the growth inhibitory effects of Ras[[20-23](#_ENREF_20)]. Interestingly, RASSF family proteins are often down-regulated during the process of oncogenesis[[22](#_ENREF_22),[23](#_ENREF_23)], and genes of the RASSF family have been reported to be epigenetically silenced in certain types of human cancers[[23](#_ENREF_23)]. RASSF6 is the last reported member of the RASSF family proteins. Of the 96 patients, we found that more than half of the tumors showed negative RASSF6 expression (53.1%), and only 16 (16.7%) patients’ tumor tissue stained strongly for RASSF6. Our findings agree with earlier studies demonstrating that RASSF6 is often down-regulated in primary human tumors. We did not find any significant differences in the distribution of age, gender and tumor location between groups based upon OPN expression. The PDAC in the present study tended to be larger (mean diameter = 3.7 cm, with 86% being T3); this fact can be explained by difficult early diagnoses, especially in developing regions, such as where our hospital located.

Until now, only one study investigated the clinical value of RASSF6 expression in cancer: Wen *et al*[[18](#_ENREF_18)] reported that RASSF6 expression was an independent prognostic factor for gastric cancer patients and strong RASSF6 expression was associated with better overall survival compared with patients whose tumors are RASSF6 negative. Using IHC, we found that decreased RASSF6 protein expression seemed to be associated with higher T stage tumors, and RASSF6 was moderately or strongly expressed to a greater degree in tumors without perineural invasion. Multivariate analysis confirmed that the RASSF6 expression level was an independent prognostic factor for overall survival (*P* < 0.001). In this present study, survival analysis also showed that increased RASSF6 expression promoted a significant survival advantage that persisted in multivariate analysis. Our prognostic results are in accordance with a study performed in gastric cancer patients. The previous study by Wen *et al*[[18](#_ENREF_18)] demonstrated a significant correlation between RASSF6 expression and tumor differentiation, but our findings are different. In our data, the RASSF6 expression tended to be negative in larger tumors or higher T stage ones, but not positive in poorly differentiated tissues. Coupled with the finding that RASSF6 expression was decreased in metastatic tissues revealed by western blot and that RASSF6 stained strongly in chronic pancreatitis tissues, we proposed that RASSF6 expression might decrease along with progression of cancer.

Interestingly, tumors with perineural invasion showed a significant decrease in the RASSF6 expression level compared to those without perineural invasion (*P* = 0.026) in our study, and RASSF6 protein expression in tumor cells that invaded nerve tissues was also decreased compared with adjacent PDAC tumor cells. Perineural invasion has been reported in certain types of cancer, including pancreatic, prostate, colorectal, *etc*.[[24](#_ENREF_24),[25](#_ENREF_25)]. PDACs have the highest incidences of perineural invasion among cancers[[26](#_ENREF_26),[27](#_ENREF_27)], and the presence of perineural invasion was reported as a strong poor prognostic factor for both overall survival and disease-free survival[[28](#_ENREF_28),[29](#_ENREF_29)]. Meanwhile, perineural invasion is considered to be the primary cause of abdominal pain in pancreatic cancer patients[[25](#_ENREF_25)]. Therefore, targeting perineural invasion is an attractive therapeutic approach for pancreatic cancer. Until now, most of the studies on perineural invasion focused on the interaction between cancer cells and nerves. Therefore, research on the biological mechanism of perineural invasion was limited to the ligand-receptor inter-attraction between tumor cells and nerve tissues[[25](#_ENREF_25)]. Few studies have examined the characteristics of the tumor cells themselves and the roles of tumor stromal components, such as fibroblasts, infiltrating immune cells and extracellular matrix proteins in perineural invasion. Our findings regarding the relationship between altered RASSF6 expression and perineural invasion indicated a potential role of RASSF6 in the process of perineural invasion. The effect of the RASSF6 protein in perineural invasion and whether the expression of RASSF6 was regulated by an endopathic approach or external stimuli need further study. Recently, a study reported that RASSF6 expression in adipocytes was down-regulated by interacting with macrophages[[30](#_ENREF_30)], indicating a potential role of infiltrating macrophages in perineural invasion though regulating RASSF6 expression.

The other notable structural feature of RASSF6 is the C-terminal Salvador-RASSF-Hippo (SARAH) domain, which mediates the antagonism effect of RASSF on the Drosophila Hippo pathway[[31](#_ENREF_31)]. The Hippo pathway is a key regulator of organ size and cell density through regulating cell proliferation, apoptosis, and stem cell/progenitor cell expansion[[32](#_ENREF_32)]. The Hippo signaling cascade antagonizes the transcriptional coactivator yes-associated protein (YAP) whose overexpression has been reported in different human tumors, including colon, prostate, ovarian, and lung cancer[[33](#_ENREF_33)]. Two recent studies reported a crucial requirement for the Hippo signaling pathway in regulating the development of the pancreas[[33](#_ENREF_33),[34](#_ENREF_34)]. However, the role of the Hippo pathway in pancreatic cancer still remains unclear. Ikeda e*t al*[[32](#_ENREF_32)] recently found that RASSF6 antagonizes Hippo signaling and mediates apoptosis through a pathway that is parallel to the canonical Hippo pathway. In our present study, we also defined a crucial role of the RASSF6 protein in the development of PDAC. These findings suggested that the Hippo pathway and/or YAP might play a potentially important role in pancreatic cancer.

In conclusion, this is the first report to demonstrate the clinical significance of RASSF6 expression in PDAC. RASSF6 expression appears to be decreased with the progression of pancreatic cancer and is significantly associated with poor prognosis. Our results suggest that the presence of RASSF6 expression in PDAC may have a protective effect independent of tumor stage in resectable tumors. In addition, we believe that these results provide a basis for further, more detailed studies on perineural invasion and the Hippo pathway in pancreatic cancer.

**COMMENTS**

***Background***

Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant digestive tumor with a very poor prognosis. Inappropriate activation of Ras proteins is a hallmark of PDAC, which promotes a variety of malignant phenotypes, including enhanced growth, loss of contact inhibition, a reduced requirement for growth factors, enhanced motility and invasion and resistance to apoptosis.

***Research frontiers***

Recently, RASSF6 was identified as a new negative effector of the RAS protein, which demonstrates a tumor suppressor function. In 239-T cells, a dramatic synergistic activation of cell death was observed when the cells were transfected with activated K-Ras and RASSF6 together, and siRNA knockdown of RASSF6 expression in human lung tumor cells increases tumorigenicity. However, the role of RASSF6 in PDAC is still unknown. In this study, the authors demonstrate that RASSF6 expression is decreased in PDAC tissues and lymph node metastases, and the expression of RASSF6 has a significant impact on the survival of patients with PDAC. These results might indicate that RASSF6 could be a potential prognostic factor for PDAC patients.

***Innovations and breakthroughs***

This is the first study to report that RASSF6 is decreased in PDAC and that the expression of RASSF6 might decrease with the development of cancer.

***Applications***

This study showed that the RASSF6 expression level may be used as a potential predictor of prognosis in pancreatic cancer.

***Terminology***

RASSF6 is the abbreviation of Ras association (RalGDS/AF-6) domain family member 6. This gene encodes a member of the Ras-association domain family (RASSF). Members of this family form the core of a highly conserved tumor suppressor network, the Salvador-Warts-Hippo pathway. The protein encoded by this gene is a Ras effector protein that induces apoptosis. A genomic region containing this gene has been linked to susceptibility to viral bronchiolitis. Alternative splicing results in multiple transcript variants and protein isoforms.

***Peer-review***

This is an interesting study with valuable information regarding the expression and clinical impact of RASSF6 in pancreatic ductal adenocarcinoma.

**REFERENCES**

1 **Ferlay J**, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *Int J Cancer* 2010; **127**: 2893-2917 [PMID: 21351269 DOI: 10.1002/ijc.25516]

2 **Jones S**, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, Hong SM, Fu B, Lin MT, Calhoun ES, Kamiyama M, Walter K, Nikolskaya T, Nikolsky Y, Hartigan J, Smith DR, Hidalgo M, Leach SD, Klein AP, Jaffee EM, Goggins M, Maitra A, Iacobuzio-Donahue C, Eshleman JR, Kern SE, Hruban RH, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. *Science* 2008; **321**: 1801-1806 [PMID: 18772397 DOI: 10.1126/science.1164368]

3 **Sun C**, Rosendahl AH, Ansari D, Andersson R. Proteome-based biomarkers in pancreatic cancer. *World J Gastroenterol* 2011; **17**: 4845-4852 [PMID: 22171124 DOI: 10.3748/wjg.v17.i44.4845]

4 **Biankin AV,** Waddell N, Kassahn KS, Gingras MC, Muthuswamy LB, Johns AL, Miller DK, Wilson PJ, Patch AM, Wu J, Chang DK, Cowley MJ, Gardiner BB, Song S, Harliwong I, Idrisoglu S, Nourse C, Nourbakhsh E, Manning S, Wani S, Gongora M, Pajic M, Scarlett CJ, Gill AJ, Pinho AV, Rooman I, Anderson M, Holmes O, Leonard C, Taylor D, Wood S, Xu Q, Nones K, Fink JL, Christ A, Bruxner T, Cloonan N, Kolle G, Newell F, Pinese M, Mead RS, Humphris JL, Kaplan W, Jones MD, Colvin EK, Nagrial AM, Humphrey ES, Chou A, Chin VT, Chantrill LA, Mawson A, Samra JS, Kench JG, Lovell JA, Daly RJ, Merrett ND, Toon C, Epari K, Nguyen NQ, Barbour A, Zeps N, Kakkar N, Zhao F, Wu YQ, Wang M, Muzny DM, Fisher WE, Brunicardi FC, Hodges SE, Reid JG, Drummond J, Chang K, Han Y, Lewis LR, Dinh H, Buhay CJ, Beck T, Timms L, Sam M, Begley K, Brown A, Pai D, Panchal A, Buchner N, De Borja R, Denroche RE, Yung CK, Serra S, Onetto N, Mukhopadhyay D, Tsao MS, Shaw PA, Petersen GM, Gallinger S, Hruban RH, Maitra A, Iacobuzio-Donahue CA, Schulick RD, Wolfgang CL, Morgan RA, Lawlor RT, Capelli P, Corbo V, Scardoni M, Tortora G, Tempero MA, Mann KM, Jenkins NA, Perez-Mancera PA, Adams DJ, Largaespada DA, Wessels LF, Rust AG, Stein LD, Tuveson DA, Copeland NG, Musgrove EA, Scarpa A, Eshleman JR, Hudson TJ, Sutherland RL, Wheeler DA, Pearson JV, McPherson JD, Gibbs RA, Grimmond SM. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. *Nature* 2012; **491**: 399-405 [PMID: 23103869 DOI: 10.1038/nature11547]

5 **Iacobuzio-Donahue CA**. Genetic evolution of pancreatic cancer: lessons learnt from the pancreatic cancer genome sequencing project. *Gut* 2012; **61**: 1085-1094 [PMID: 21749982 DOI: 10.1136/gut.2010.236026]

6 **van Heek T**, Rader AE, Offerhaus GJ, McCarthy DM, Goggins M, Hruban RH, Wilentz RE. K-ras, p53, and DPC4 (MAD4) alterations in fine-needle aspirates of the pancreas: a molecular panel correlates with and supplements cytologic diagnosis. *Am J Clin Pathol* 2002; **117**: 755-765 [PMID: 12090425 DOI: 10.1309/5RQ0-JCQU-5XF2-51LQ]

7 **Haeno H**, Gonen M, Davis MB, Herman JM, Iacobuzio-Donahue CA, Michor F. Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. *Cell* 2012; **148**: 362-375 [PMID: 22265421 DOI: 10.1016/j.cell.2011.11.060]

8 **di Magliano MP**, Logsdon CD. Roles for KRAS in pancreatic tumor development and progression. *Gastroenterology* 2013; **144**: 1220-1229 [PMID: 23622131 DOI: 10.1053/j.gastro.2013.01.071]

9 **Reichert M**, Rustgi AK. Pancreatic ductal cells in development, regeneration, and neoplasia. *J Clin Invest* 2011; **121**: 4572-4578 [PMID: 22133881 DOI: 10.1172/JCI57131]

10 **Malumbres M**, Barbacid M. RAS oncogenes: the first 30 years. *Nat Rev Cancer* 2003; **3**: 459-465 [PMID: 12778136 DOI: 10.1038/nrc1097]

11 **Frame S**, Balmain A. Integration of positive and negative growth signals during ras pathway activation in vivo. *Curr Opin Genet Dev* 2000; **10**: 106-113 [PMID: 10679397 DOI: S0959-437X(99)00052-0]

12 **Cox AD**, Der CJ. The dark side of Ras: regulation of apoptosis. *Oncogene* 2003; **22**: 8999-9006 [PMID: 14663478 DOI: 10.1038/sj.onc.1207111]

13 **Nicke B**, Bastien J, Khanna SJ, Warne PH, Cowling V, Cook SJ, Peters G, Delpuech O, Schulze A, Berns K, Mullenders J, Beijersbergen RL, Bernards R, Ganesan TS, Downward J, Hancock DC. Involvement of MINK, a Ste20 family kinase, in Ras oncogene-induced growth arrest in human ovarian surface epithelial cells. *Mol Cell* 2005; **20**: 673-685 [PMID: 16337592 DOI: S1097-2765(05)01688-6]

14 **Sherwood V**, Recino A, Jeffries A, Ward A, Chalmers AD. The N-terminal RASSF family: a new group of Ras-association-domain-containing proteins, with emerging links to cancer formation. *Biochem J* 2010; **425**: 303-311 [PMID: 20025613 DOI: 10.1042/BJ20091318]

15 **Allen NP**, Donninger H, Vos MD, Eckfeld K, Hesson L, Gordon L, Birrer MJ, Latif F, Clark GJ. RASSF6 is a novel member of the RASSF family of tumor suppressors. *Oncogene* 2007; **26**: 6203-6211 [PMID: 17404571 DOI: 1210440]

16 **Hesson LB**, Dunwell TL, Cooper WN, Catchpoole D, Brini AT, Chiaramonte R, Griffiths M, Chalmers AD, Maher ER, Latif F. The novel RASSF6 and RASSF10 candidate tumour suppressor genes are frequently epigenetically inactivated in childhood leukaemias. *Mol Cancer* 2009; **8**: 42 [PMID: 19570220 DOI: 10.1186/1476-4598-8-42]

17 **Sherwood V**, Manbodh R, Sheppard C, Chalmers AD. RASSF7 is a member of a new family of RAS association domain-containing proteins and is required for completing mitosis. *Mol Biol Cell* 2008; **19**: 1772-1782 [PMID: 18272789 DOI: 10.1091/mbc.E07-07-0652]

18 **Wen Y**, Wang Q, Zhou C, Yan D, Qiu G, Yang C, Tang H, Peng Z. Decreased expression of RASSF6 is a novel independent prognostic marker of a worse outcome in gastric cancer patients after curative surgery. *Ann Surg Oncol* 2011; **18**: 3858-3867 [PMID: 21442347 DOI: 10.1245/s10434-011-1668-5]

19 **Vos MD**, Ellis CA, Bell A, Birrer MJ, Clark GJ. Ras uses the novel tumor suppressor RASSF1 as an effector to mediate apoptosis. *J Biol Chem* 2000; **275**: 35669-35672 [PMID: 10998413 DOI: 10.1074/jbc.C000463200]

20 **Vos MD**, Ellis CA, Elam C, Ulku AS, Taylor BJ, Clark GJ. RASSF2 is a novel K-Ras-specific effector and potential tumor suppressor. *J Biol Chem* 2003; **278**: 28045-28051 [PMID: 12732644 DOI: 10.1074/jbc.M300554200]

21 **Eckfeld K**, Hesson L, Vos MD, Bieche I, Latif F, Clark GJ. RASSF4/AD037 is a potential ras effector/tumor suppressor of the RASSF family. *Cancer Res* 2004; **64**: 8688-8693 [PMID: 15574778 DOI: 64/23/8688]

22 **Agathanggelou A**, Cooper WN, Latif F. Role of the Ras-association domain family 1 tumor suppressor gene in human cancers. *Cancer Res* 2005; **65**: 3497-3508 [PMID: 15867337 DOI: 65/9/3497]

23 **Djos A**, Martinsson T, Kogner P, Carén H. The RASSF gene family members RASSF5, RASSF6 and RASSF7 show frequent DNA methylation in neuroblastoma. *Mol Cancer* 2012; **11**: 40 [PMID: 22695170 DOI: 10.1186/1476-4598-11-40]

24 **Marchesi F**, Piemonti L, Mantovani A, Allavena P. Molecular mechanisms of perineural invasion, a forgotten pathway of dissemination and metastasis. *Cytokine Growth Factor Rev* 2010; **21**: 77-82 [PMID: 20060768 DOI: 10.1016/j.cytogfr.2009.11.001]

25 **Bapat AA**, Hostetter G, Von Hoff DD, Han H. Perineural invasion and associated pain in pancreatic cancer. *Nat Rev Cancer* 2011; **11**: 695-707 [PMID: 21941281 DOI: 10.1038/nrc3131]

26 **Liu B**, Lu KY. Neural invasion in pancreatic carcinoma. *Hepatobiliary Pancreat Dis Int* 2002; **1**: 469-476 [PMID: 14607730]

27 **Pour PM**, Bell RH, Batra SK. Neural invasion in the staging of pancreatic cancer. *Pancreas* 2003; **26**: 322-325 [PMID: 12717262]

28 **Chen JW**, Bhandari M, Astill DS, Wilson TG, Kow L, Brooke-Smith M, Toouli J, Padbury RT. Predicting patient survival after pancreaticoduodenectomy for malignancy: histopathological criteria based on perineural infiltration and lymphovascular invasion. *HPB* (Oxford) 2010; **12**: 101-108 [PMID: 20495653 DOI: 10.1111/j.1477-2574.2009.00140.x]

29 **di Mola FF**, di Sebastiano P. Pain and pain generation in pancreatic cancer. *Langenbecks Arch Surg* 2008; **393**: 919-922 [PMID: 18193269 DOI: 10.1007/s00423-007-0277-z]

30 **Sanada Y**, Kumoto T, Suehiro H, Nishimura F, Kato N, Hata Y, Sorisky A, Yanaka N. RASSF6 expression in adipocytes is down-regulated by interaction with macrophages. *PLoS One* 2013; **8**: e61931 [PMID: 23626755 DOI: 10.1371/journal.pone.0061931]

31 **Pan D**. Hippo signaling in organ size control. *Genes Dev* 2007; **21**: 886-897 [PMID: 17437995 DOI: 21/8/886]

32 **Ikeda M**, Kawata A, Nishikawa M, Tateishi Y, Yamaguchi M, Nakagawa K, Hirabayashi S, Bao Y, Hidaka S, Hirata Y, Hata Y. Hippo pathway-dependent and -independent roles of RASSF6. *Sci Signal* 2009; **2**: ra59 [PMID: 19797269 DOI: 10.1126/scisignal.2000300]

33 **George NM**, Day CE, Boerner BP, Johnson RL, Sarvetnick NE. Hippo signaling regulates pancreas development through inactivation of Yap. *Mol Cell Biol* 2012; **32**: 5116-5128 [PMID: 23071096 DOI: 10.1128/MCB.01034-12]

34 **Gao T**, Zhou D, Yang C, Singh T, Penzo-Méndez A, Maddipati R, Tzatsos A, Bardeesy N, Avruch J, Stanger BZ. Hippo signaling regulates differentiation and maintenance in the exocrine pancreas. *Gastroenterology* 2013; **144**: 1543-153, 1553.e1 [PMID: 23454691 DOI: 10.1053/j.gastro.2013.02.037]

**P-Reviewer:** Mosteiro L, Sun YW **S-Editor:** Qi Y **L-Editor: E-Editor:**

**Figure 1** **Representative images of chronic pancreatitis and pancreatic ductal adenocarcinoma tissues immunostained for RASSF6.** Representative micrographs of RASSF6 in pancreatic ductal adenocarcinoma (PDAC) cancerous tissue or chronic pancreatitis tissues by immunohistochemistry. a1: Diffused cytoplasmic RASSF6 staining in chronic pancreatitis tissues.a2: Representative negative staining of RASSF6 in PDAC.a3: Extreme strong RASSF6 staining in pancreas islet (black arrow).b1-b3: Strong positive RASSF6 staining in PDAC.c1-c3: Weak positive RASSF6 staining in PDAC. Magnifications: × 100 for a1, a2, b1, b2, c1 and c2; × 200 for a3, b3 and c3.![C:\Users\qiyuan\AppData\Roaming\Tencent\Users\409881474\QQ\WinTemp\RichOle\Q8C]1)KLKSK`EB0S~K)H2]B.png]()

**Figure 2 qRT-PCR evaluation of RASSF6 expression in pancreatic ductal adenocarcinoma tissues.** A: RASSF6 mRNA levels in pancreatic ductal adenocarcinoma (PDAC) tissues were significant decreased compared with its levels of chronic pancreatitis tissues (*P* < 0.001). B: Groups were made according to the immunohistochemical results, and the consistency between immunohistochemical results and PCR results were evaluated through *t* test. Result showed that immunohistochemical scores were in keeping with RASSF6 mRNA levels (*P* < 0.001). C, D: RASSF6 mRNA and protein expression levels were evaluated by qRT-PCR and Western blot in 16 cases with strong RASSF6 immunohistochemical staining. Even in these PDAC tissues with strong positive RASSF6 staining, both the mRNA expression (C: *P* = 0.033) and protein levels (D: *P* = 0.049) were still less than para-tumor tissues.

 

 

**Figure 3 Survival curve of patients with pancreatic ductal adenocarcinoma in regards to RASSF6 expression.** A: There was a significant correlation between RASSF6 expression levels and overall survival (*P* = 0.009); B: Overall survival of patients with strong positive RASSF6 staining was significant higher than overall survival of those whose tumor was negative staining (*P* = 0.006); C: Weak positive staining *vs* negative staining (*P* = 0.047). D: Overall survival of patients with positive RASSF6 staining (strong positive plus weak positive staining) still remained better than survival of patients with negative staining of RASSF6 (*P* = 0.004).

 

![C:\Users\qiyuan\AppData\Roaming\Tencent\Users\409881474\QQ\WinTemp\RichOle\TB51X9$[KX]7FY6I{7WU10P.png]() 

**Table 1 Correlation between RASSF6 expression and clinicopathological characters in patients with pancreatic ductal adenocarcinoma**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Parameter** | **Total*****n* = 96** | **RASSF6****Negative*****n* = 51** | **RASSF6****Weak*****n* = 29** | **RASSF6****Positive*****n* = 16** | ***P* value** |
| Age (yr) |  |  |  |  | 0.115 |
| mean (range)  | 60.7 (31-77) | 59.3 (77-45) | 61.3 (31-77) | 64.3 (54-70) |  |
| Gender |  |  |  |  | 0.563 |
|  Male | 51 | 29 | 13 | 9 |  |
|  Female | 45 | 22 | 16 | 7 |  |
| Location of tumor |  |  |  |  | 0.777 |
|  Head | 81 | 42 | 22 | 13 |  |
|  Body/tail | 15 | 9 | 7 | 3 |  |
| Differentiation |  |  |  |  | 0.138 |
|  Well | 35 | 14 | 11 | 10 |  |
|  Moderate | 37 | 22 | 12 | 3 |  |
|  Poor | 24 | 15 | 6 | 3 |  |
| Tumor diameter (cm) |  |  |  |  | 0.613 |
| mean(range) | 3.7 (1.5-8.0) | 3.8 (1.5-8.0) | 3.5 (1.5-6.0) | 3.9 (7.5-5.5) |  |
| UICC/TNM stage |  |  |  |  | 0.200 |
| pI | 6 | 4 | 0 | 2 |  |
| pII | 90 | 47 | 29 | 14 |  |
| T-stage |  |  |  |  | 0.0471, 0.0762 |
|  pT1 | 5 | 3 | 2 | 0 |  |
|  pT2 | 10 | 3 | 2 | 5 |  |
|  pT3 | 81 | 45 | 25 | 11 |  |
| N-stage |  |  |  |  | 0.124 |
|  pN0 | 35 | 23 | 9 | 3 |  |
|  pN1 | 61 | 28 | 20 | 13 |  |
| Portal vein invasion |  |  |  |  | 0.698 |
|  Negative | 84 | 45 | 26 | 13 |  |
|  Positive | 12 | 6 | 3 | 3 |  |
| Perineural invasion |  |  |  |  | 0.026 |
|  Negative | 31 | 11 | 11 | 9 |  |
|  Positive | 65 | 40 | 18 | 7 |  |
| Surgical margins |  |  |  |  | 0.694 |
|  Negative | 79 | 43 | 24 | 12 |  |
|  Positive | 17 | 8 | 5 | 4 |  |

1Pearson’s χ2 test; 2Fisher’s exact test. All other p values were carried out by Pearson’s χ2 test.

**Table 2 Potential predictors of overall survival in 96 patients with pancreatic ductal adenocarcinoma undergoing radical surgery**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Variable** | **Univariate** |  | **Multivariate** |  |
|  | ***P* value** | **HR** | **95% CI** | ***P* value** |
| Tumor diameter | 0.010 | 1.172 | 0.992-1.385 | 0.062 |
| T stage | 0.012 | 2.355 | 1.413-3.925 | 0.031 |
| Differentiation | 0.016 | 2.397 | 1.665-3.451 | < 0.001 |
| Perineural invasion | 0.076 | 2.236 | 1.163-4.300 | 0.016 |
| Rassf6 expression | 0.021 | 4.620 | 2.027-10.527 | 0.006 |

HR: Hazard ratio; CI: Confidence interval.